Brief Description
ReRx is developing novel oral small molecule therapeutics to treat patients with severe metabolic diseases including obesity, metabolic syndrome, diabetes, and liver diseases. The company's therapeutics target metabolic pathways involved in regulating energy homeostasis and improve treatment outcomes compared to similar pharmacological agents.
Obesity and its associated metabolic diseases remain leading causes of preventable illness and mortality worldwide. Current front-line treatments, notably injectable incretin analogs that suppress appetite and reduce food intake, have demonstrated clinical benefit but face challenges related to tolerability, cost, and long-term adherence. ReRx’s approach is distinct and complementary: rather than tackling appetite regulation, ReRx-001 addresses energy utilization and metabolic efficiency, offering a novel approach for weight/health management and metabolic health.
Inventors
Chi Zhu, Anders Michael Naar, Justin Yu-Sun Lee
Company Founders
UC Berkeley Professor Anders Naar (UC Berkeley Postdoc), Justin Lee (UC Berkeley, BA, 2019, Molecular and Cell Biology, Immunology, Ph.D., 2025, Metaboloic Biology), Prabha Ibrahim, Bethany Chen, Michael Tippie
Timeline
- 2023. Company founded; Joins Berkeley Skydeck Cohort 17